CYTR estoy leyendo de cytr y su aldoxorubicin, aunque esto no haga que suba..., es un medicamento que combina el
doxorubicin,un medicamento contra el cancer, que por sus fuertes efectos secundarios y su color llaman "diablo, o muerte roja" y un
acid sensitive linker (N-ε-maleimidocaproic acid hydrazide, or EMCH). Es algo sensible al ácido que es dónde crecen tumores y alli libera la dosis de doxorubicin.
Noviembre 2016: http://www.cytrx.com/downloads/BWT_113016_Cytrx.pdf Curioso que comentan que tuvieron unos resultados "comparables" con los de Yondelis, de
Pharmamar, sí! Tambien esta con el soft tissue sarcoma ese y Pharmamar lleva meses de buena subida la jodia, En fin que tuvieron resultados parecidos pero con menos efectos adversos y con una dosificación mucho más rápida
"Although Levitt conceded it’s “hard to compare one study to the other,” he said the phase III results as sorted further suggest that
aldoxorubicin performed in a manner
“comparable” to Yondelis (trabectedin), from Madrid-based
Pharmamar SA and partnered with Johnson & Johnson, of New Brunswick, N.J. Yondelis is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen. Patients treated with Yondelis must be medicated fi rst with dexamethasone and get the
Yondelis infusion over a 24-hour period. “With
aldoxorubicin, they receive a 30-minute infusion and maybe stay around [the clinic] for another 30 minutes, and then can go home,” he said. “The side effect profi le with aldoxorubicin is what you would expect with doxorubicin. We saw no signifi cant cardiac events, unlike Yondelis, which has a cardiomyopathy issue in about 6 percent of patients.” More parsing of the data will look at differences in patient populations in the aldoxorubicin study, and will include “at least 30 different non-specifi ed endpoints for more color on what may have contributed to the outcome,” he said. Cytrx offi cials “met with about a dozen of the investigators in this study, and they were all very positive about aldoxorubicin,” he added. “It certainly is an active drug.” Shares of Cytrx (NASDAQ:CYTR) traded high in the premarket activity Tuesday but ended at 57 cents, up 1 cent"
Paso algo con un primer estudio malo, y creoque ahora esperamos el (OS):
Patients continue to be followed for overall survival (OS), a secondary endpoint, and Cytrx expects the OS data to be available in 2017
esta muy tranquilo lo que sigo hoy
